Product
Help
Pricing
About
Jobs
Log in
Get started
Work
Add to collection
Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
HTML
PDF
Details
Locations
Year:
2019
Type:
review
Source:
Journal of Hepatology
DOI:
10.1016/j.jhep.2019.01.028
Authors:
Josep M. Llovet,
Robert Montal,
Augusto Villanueva
Institutions:
Institució Catalana de Recerca i Estudis Avançats,
Hospital Clínic de Barcelona,
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer,
Tisch Cancer Institute,
Universitat de Barcelona,
Icahn School of Medicine at Mount Sinai
show all 6
Language:
English
Topic:
Hepatocellular Carcinoma Treatment and Prognosis
Subfield:
Hepatology
Field:
Medicine
Domain:
Health Sciences
Keywords:
hepatocellular carcinoma,
surrogate endpoints,
progression-free survival,
time to progression,
overall survival,
sorafenib,
lenvatinib,
regorafenib,
cabozantinib,
ramucirumab,
nivolumab,
objective response rate,
trial design,
hazard ratio
show all 14
SDG:
Good health and well-being
Open Access status:
bronze
Funders:
U.S. Department of Defense,
Samuel Waxman Cancer Research Foundation,
Cancer Research UK,
European Commission,
Generalitat de Catalunya,
National Cancer Institute
show all 6
Awards:
G4119076191,
G4139524798,
The Tisch Cancer Institute - Cancer Center Support Grant
OpenAlex ID:
W2933348020
FWCI:
3.61
Cites:
129
Cited by:
248
Related to:
10